590 related articles for article (PubMed ID: 30922261)
1. Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial.
Chen LC; Chiou WY; Lin HY; Lee MS; Lo YC; Huang LW; Chang CM; Hung TH; Lin CW; Tseng KC; Liu DW; Hsu FC; Hung SK
BMC Cancer; 2019 Mar; 19(1):275. PubMed ID: 30922261
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360).
Comito T; Loi M; Franzese C; Clerici E; Franceschini D; Badalamenti M; Teriaca MA; Rimassa L; Pedicini V; Poretti D; Solbiati LA; Torzilli G; Ceriani R; Lleo A; Aghemo A; Santoro A; Scorsetti M
Curr Oncol; 2022 Nov; 29(11):8802-8813. PubMed ID: 36421345
[No Abstract] [Full Text] [Related]
3. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
Sebastian NT; Miller ED; Yang X; Diaz DA; Tan Y; Dowell J; Spain J; Rikabi A; Elliott E; Knopp M; Williams TM
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1276-1283. PubMed ID: 32712254
[TBL] [Abstract][Full Text] [Related]
4. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
[No Abstract] [Full Text] [Related]
5. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma.
Paik EK; Kim MS; Jang WI; Seo YS; Cho CK; Yoo HJ; Han CJ; Park SC; Kim SB; Kim YH
Radiat Oncol; 2016 Feb; 11():22. PubMed ID: 26896371
[TBL] [Abstract][Full Text] [Related]
6. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies.
Kimura T; Aikata H; Doi Y; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Katsuta T; Kenjo M; Murakami Y; Awai K; Chayama K; Nagata Y
Technol Cancer Res Treat; 2018 Jan; 17():1533033818783450. PubMed ID: 29963972
[TBL] [Abstract][Full Text] [Related]
8. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma.
Chiang CL; Chan MKH; Yeung CSY; Ho CHM; Lee FAS; Lee VWY; Wong FCS; Blanck O
Strahlenther Onkol; 2019 Mar; 195(3):254-264. PubMed ID: 30413833
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.
Shen PC; Chang WC; Lo CH; Yang JF; Lee MS; Dai YH; Lin CS; Fan CY; Huang WY
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):307-318. PubMed ID: 31175903
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
11. Chemoembolization combined radiofrequency ablation vs. chemoembolization alone for treatment of beyond the Milan criteria viable hepatocellular carcinoma (CERFA): study protocol for a randomized controlled trial.
Lee SK; Yang H; Kwon JH; Shim DJ; Kim D; Nam SW; Yoo SH; Bae SH; Lee A; Lee YJ; Jeon C; Jang JW; Sung PS; Chun HJ; Kim SH; Choi JI; Oh JS; Yang YJ
Trials; 2023 Mar; 24(1):234. PubMed ID: 36978150
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.
Takeda A; Sanuki N; Tsurugai Y; Iwabuchi S; Matsunaga K; Ebinuma H; Imajo K; Aoki Y; Saito H; Kunieda E
Cancer; 2016 Jul; 122(13):2041-9. PubMed ID: 27062278
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Honda Y; Kimura T; Aikata H; Kobayashi T; Fukuhara T; Masaki K; Nakahara T; Naeshiro N; Ono A; Miyaki D; Nagaoki Y; Kawaoka T; Takaki S; Hiramatsu A; Ishikawa M; Kakizawa H; Kenjo M; Takahashi S; Awai K; Nagata Y; Chayama K
J Gastroenterol Hepatol; 2013 Mar; 28(3):530-6. PubMed ID: 23216217
[TBL] [Abstract][Full Text] [Related]
14. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Eggert T; Greten TF
Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
[TBL] [Abstract][Full Text] [Related]
15. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.
Choi BO; Choi IB; Jang HS; Kang YN; Jang JS; Bae SH; Yoon SK; Chai GY; Kang KM
BMC Cancer; 2008 Nov; 8():351. PubMed ID: 19038025
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization.
Kang JK; Kim MS; Cho CK; Yang KM; Yoo HJ; Kim JH; Bae SH; Jung DH; Kim KB; Lee DH; Han CJ; Kim J; Park SC; Kim YH
Cancer; 2012 Nov; 118(21):5424-31. PubMed ID: 22570179
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Honda Y; Kimura T; Aikata H; Nakahara T; Naeshiro N; Tanaka M; Miyaki D; Nagaoki Y; Kawaoka T; Takaki S; Hiramatsu A; Waki K; Ishikawa M; Kakizawa H; Kenjo M; Awai K; Nagata Y; Chayama K
Hepatogastroenterology; 2014; 61(129):31-6. PubMed ID: 24895789
[TBL] [Abstract][Full Text] [Related]
19. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis.
Wong TC; Chiang CL; Lee AS; Lee VH; Yeung CS; Ho CH; Cheung TT; Ng KK; Chok SH; Chan AC; Dai WC; Wong FC; Luk MY; Leung TW; Lo CM
Surg Oncol; 2019 Mar; 28():228-235. PubMed ID: 30851906
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis.
Jun BG; Kim SG; Kim YD; Cheon GJ; Han KH; Yoo JJ; Kim YS; Jeong SW; Jang JY; Lee SH; Park S; Kim HS
PLoS One; 2018; 13(10):e0206381. PubMed ID: 30379885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
